Showing results (231-240 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|July 16, 2021
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinibKeisuke Kidoguch, Motoharu Shibusawa, Tetsuya TanimotoInvestigational New Drugs|June 12, 2021
Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I studyAkira Kawai, Norifumi Naka, Akihiko Shimomura, et al.Investigational New Drugs|July 21, 2021
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumorsPaul N M Cheng, Angela M Liu, Alberto Bessudo, et al.Investigational New Drugs|January 1, 1986
Effects of the new mitotic inhibitor pyrimidinsulfone NY 4137 on human cells in vitro and on colchicine binding to tubulinM E Nygaard, J M Dornish, R Oftebro, et al.Investigational New Drugs|January 1, 1986
Activity of RA-700, a cyclic hexapeptide from Rubiae Radix, in the human tumor clonogenic assayK Inoue, T Mukaiyama, T Kobayashi, et al.Investigational New Drugs|January 1, 1986
A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacyS A Weiner, E A Surwit, V E Graham, et al.Investigational New Drugs|January 1, 1986
Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasiaY M Peng, D S Alberts, V Graham, et al.Investigational New Drugs|January 1, 1985
Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitorA M Maddox, M J Keating, K E McCredie, et al.Investigational New Drugs|January 1, 1997
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancyP J Creaven, R Perez, L Pendyala, et al.Investigational New Drugs|January 1, 1997
Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group studyJ G Wall, J K Benedetti, M A O'Rourke, et al.Pageof 372